Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04457817 · ClinicalTrials.gov registry record
Compensatory Reserve Index (CRI) for Management of COVID-19
A clinical trial, sponsored by University of Colorado, Denver.
- Terminated
- Registry status
- 16
- Enrollment target
NCT04457817 is a clinical trial that was terminated before completion, run by University of Colorado, Denver. The registered enrollment target is 16 participants.
The verdict
NCT04457817 was terminated before completion, sponsored by University of Colorado, Denver.
- TERMINATED
- Registry status
- 16 participants
- Enrollment target
Study Summary
The FDA has approved the CipherOx CRI T1 Tablet for use in subjects aged 19-36, and that this study aims to evaluate the device in subjects aged outside of this range and is being used off label. The FDA determined the Cipher OX CRI T1 Tablet to be a class II device in 2016, and additional research has been done since the FDA determination to further support the use of the device outside of its current labeling.
Interventions
- DEVICE CRI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2020-12-01 |
| Est. Completion | 2021-04-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04457817
The ClinicalTrials.gov registry entry for NCT04457817 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CRI is the first listed.
NCT04457817 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04457817 about?
NCT04457817 is a clinical study titled "Compensatory Reserve Index (CRI) for Management of COVID-19". The FDA has approved the CipherOx CRI T1 Tablet for use in subjects aged 19-36, and that this study aims to evaluate the device in subjects aged outside of this range and is being used off label. The FDA determined the Cipher OX CRI T1 Tablet to be a class II device in 2016, and additional research...
What is the current status of trial NCT04457817?
This trial is currently terminated. The enrollment target is 16 participants. The study started on 2020-12-01. Estimated completion is 2021-04-08.
What interventions are being tested in trial NCT04457817?
The interventions under investigation include: CRI (DEVICE).
Who is sponsoring clinical trial NCT04457817?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.